Optimum fractionation of radiation to combine PD‐1 blockade
暂无分享,去创建一个
F. Teng | Peiliang Wang | Tianwen Yin | Yungang Wang | Jinming Yu | Xiao Ju
[1] F. Teng,et al. Treatment-related lymphopenia impairs the treatment response of anti-PD-1 therapy in esophageal squamous cell carcinoma. , 2022, International immunopharmacology.
[2] Jinming Yu,et al. The role of exosomes in tumour immunity under radiotherapy: eliciting abscopal effects? , 2021, Biomarker research.
[3] Zhaofei Liu,et al. ICAM-1 orchestrates the abscopal effect of tumor radiotherapy , 2021, Proceedings of the National Academy of Sciences.
[4] L. Galluzzi,et al. Immunological impact of cell death signaling driven by radiation on the tumor microenvironment , 2019, Nature Immunology.
[5] N. Datta,et al. Efficacy and Safety Evaluation of the Various Therapeutic Options in Locally Advanced Cervix Cancer: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. , 2019, International journal of radiation oncology, biology, physics.
[6] Betty Y. S. Kim,et al. The Reciprocity between Radiotherapy and Cancer Immunotherapy , 2018, Clinical Cancer Research.
[7] Joe Y. Chang,et al. Time to abandon single-site irradiation for inducing abscopal effects , 2018, Nature Reviews Clinical Oncology.
[8] K. McDonald,et al. Concurrent versus non-concurrent immune checkpoint inhibition with stereotactic radiosurgery for metastatic brain disease: a systematic review and meta-analysis , 2018, Journal of Neuro-Oncology.
[9] Jinming Yu,et al. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors , 2018, Journal of Hematology & Oncology.
[10] S. Demaria,et al. Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect. , 2018, Trends in immunology.
[11] Yuquan Wei,et al. Targeting Myeloid-derived Suppressor Cells and Programmed Death Ligand 1 Confers Therapeutic Advantage of Ablative Hypofractionated Radiation Therapy Compared With Conventional Fractionated Radiation Therapy. , 2018, International journal of radiation oncology, biology, physics.
[12] J. Hesser,et al. Using immunotherapy to boost the abscopal effect , 2018, Nature Reviews Cancer.
[13] J. Wargo,et al. Immunotherapy resistance: the answers lie ahead – not in front – of us , 2017, Journal of Immunotherapy for Cancer.
[14] J. Lee,et al. Local Consolidative Therapy versus Maintenance Therapy/Observation for Patients with Oligometastatic Non-Small Cell Lung Cancer without Progression after Front-Line Systemic Therapy: Results of a Multi-Institutional Phase II Randomized Study , 2016, The Lancet. Oncology.
[15] Jinming Yu,et al. Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer. , 2015, Translational research : the journal of laboratory and clinical medicine.
[16] P. Sharma,et al. The future of immune checkpoint therapy , 2015, Science.
[17] C. Sautès-Fridman,et al. Tertiary lymphoid structures in cancer and beyond. , 2014, Trends in immunology.
[18] R. Weichselbaum,et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. , 2014, The Journal of clinical investigation.
[19] Pierre Validire,et al. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. , 2014, Cancer research.
[20] Stephen Mok,et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. , 2013, Cancer research.
[21] M. Sade-Feldman,et al. Tumor necrosis factor-α blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. , 2013, Immunity.
[22] M. Suárez-Fariñas,et al. Gene profiling of narrowband UVB-induced skin injury defines cellular and molecular innate immune responses. , 2013, The Journal of investigative dermatology.
[23] U. Syrbe,et al. TNF signaling drives myeloid-derived suppressor cell accumulation. , 2012, The Journal of clinical investigation.
[24] K. Iwamoto,et al. Maximizing tumor immunity with fractionated radiation. , 2012, International journal of radiation oncology, biology, physics.
[25] Jedd D. Wolchok,et al. Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.
[26] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[27] S. Siva,et al. Stereotactic Radiotherapy for Pulmonary Oligometastases: A Systematic Review , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[28] N. Kawashima,et al. Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody , 2009, Clinical Cancer Research.
[29] R. Weichselbaum,et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. , 2009, Blood.
[30] E. Tartour,et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] D. Pardoll,et al. Cancer immunotherapy: breaking the barriers to harvest the crop , 2004, Nature Medicine.
[32] N. Kawashima,et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. , 2004, International journal of radiation oncology, biology, physics.
[33] L. Peters,et al. Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma. , 1979, Journal of the National Cancer Institute.
[34] H. Suit,et al. Immunologic status of host and response of a methylcholanthrene‐induced sarcoma to local x‐irradiation , 1970, Cancer.
[35] S. Gettinger,et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. , 2017, The Lancet. Oncology.
[36] P. Venkat,et al. Systematic review of case reports on the abscopal effect. , 2016, Current problems in cancer.